Biggest Market Movers Today, Dec. 9: WRBY, DYN, & More

U.S. equities largely treaded water ahead of Wednesday’s Federal Reserve decision (Dow -0.38%/-179 pts, S&P 500 -0.09%, Nasdaq +0.13%), while select names saw big moves: Warby Parker jumped ~9% after highlighting a partnership with Alphabet to develop AI-powered “smart eyewear” leveraging Android VR and the Gemini model, targeting a 2026 release and presenting a potential new growth vector; Pan American Silver rallied ~11% as silver topped $60/oz and the miner’s acquisition-driven reserves, healthy balance sheet and free cash flow position it to benefit from the metal’s rally; Dyne Therapeutics plunged ~17% after announcing a $300m secondary offering following positive Duchenne muscular dystrophy trial data and a planned accelerated-approval filing, stoking dilution concerns; and SLM fell ~15% after an investor day that lowered EPS growth expectations and prompted analyst downgrades amid uncertainty over future government support for student lending.

Analysis

U.S. equities largely treaded water as investors awaited the Federal Reserve's policy decision, with the Dow down 0.38% (-179 points), the S&P 500 down 0.09% and the Nasdaq up 0.13%, reflecting a market in wait-and-see mode ahead of Wednesday’s announcement. Mixed sector moves drove individual volatility rather than a broad directional shift, consistent with the article’s description of crosscurrents and investor positioning.

Warby Parker (WRBY) jumped ~9% after detailing a partnership with Alphabet to develop AI-powered "smart eyewear" targeting a 2026 release that could incorporate Android VR and the Gemini model; this positions WRBY as a potential AI growth play but introduces execution and hype risks ahead of multi-year commercialization. Pan American Silver (PAAS) rallied ~11% as silver closed above $60/oz for the first time, and the company’s acquisition-driven reserve growth, healthy balance sheet and free cash flow suggest it is structurally better positioned to benefit from a sustained metals rally.

Dyne Therapeutics (DYN) fell ~17% after announcing a $300m secondary offering following positive DMD trial data and a planned accelerated-approval filing in mid-2026, highlighting dilution risk despite a promising clinical roadmap. SLM dropped ~15% after guiding to slower EPS growth at its investor day and prompting analyst downgrades, underscoring sensitivity to government support for student lending and the potential for further re-rating absent clearer earnings momentum.

Key Decisions for Investors

• Trim broad equity exposure or hedge beta ahead of the Fed decision to limit sensitivity to a potential surprise in rate guidance
• Consider a measured, speculative position in WRBY only if sized for binary execution risk and tied to milestones from the Alphabet partnership and 2026 product timeline
• Add or maintain exposure to high-quality silver producers like PAAS as a tactical metal play, but limit position size to reflect commodity price volatility
• Avoid initiating new positions in DYN until post-offering dilution, use-of-proceeds transparency, and regulatory filing details are available, or hedge downside if participating
• Reduce or hedge exposure to SLM until management provides clearer evidence the slower EPS growth trajectory is stabilizing or policy risk around student lending is resolved